HHS & Healthcare Contracts Intelligence — June 12, 2026

The $133.5M firm-fixed-price delivery order from HHS/ASPR provides $83.5M already outlaid, offering 3.5 years of revenue visibility (~$33.4M/year) for this private small business, won under full-and-open competition.

The cost-plus-fixed-fee contract ended September 2023 with $80.9M outlaid, offering no forward revenue; the 63% subaward rate suggests ABT Global acts as a prime integrator, not a core R&D performer.

Partner Therapeutics' $133.5M HHS contract is tied to ASPR medical preparedness priorities, which could face funding delays or cuts under a Continuing Resolution (CR) if Congress fails to pass appropriations by October 2026.

ABT Global's $83.8M CDC contract shows a 63% subaward rate ($52.3M flowed to 62 subcontractors), indicating reliance on external partners rather than core internal capabilities, which could limit follow-on award competitiveness.

Partner Therapeutics' firm-fixed-price contract carries medium pricing risk; any cost overruns in Leukine manufacturing could compress margins, though the $83.5M funded portion mitigates near-term cash flow risk.

HHS/ASPR's $133.5M commitment to Leukine signals sustained investment in medical preparedness; follow-on orders or expanded indications for the drug could benefit Partner Therapeutics or competitors in the pharmaceutical manufacturing space (NAICS 325412).

Partner Therapeutics, a small business, won a full-and-open competition without set-aside, suggesting its small business status could provide an edge in future HHS contracts with set-aside preferences, particularly under 8(a) or SDVOSB programs.

The $133.5M Partner Therapeutics contract demonstrates HHS/ASPR's continued focus on medical countermeasure stockpiling, even as COVID-19-specific funding (ABT Global's $83.8M CDC contract) winds down.

{"entity"=>"Partner Therapeutics, Inc.", "reason"=>"The $133.5M Leukine contract provides 3.5 years of revenue visibility; any option exercises or modifications could increase contract value and signal ASPR's confidence.", "trigger"=>"Contract modifications or option exercises; ASPR budget requests for medical countermeasures in FY2027"}

{"entity"=>"ABT GLOBAL LLC", "reason"=>"The $83.8M CDC contract is complete; new CDC BAA postings in mental health or physical sciences R&D could indicate follow-on work.", "trigger"=>"CDC BAA postings in NAICS 541715 or PSC AN51; ABT Global press releases on new CDC awards"}